Home | Drug Target Review

Skip to main content
Skip to navigation

Featured content

Operational data: the hidden driver of faster drug discovery

2026-04-02T14:18:00+01:00By Marcus Oxer

The key to faster, smarter drug discovery lies in data that’s often overlooked. By exposing hidden delays and inefficiencies, this data enables teams to shorten discovery cycles and progress promising candidates faster.

Article
From fragments to maps: scaling drug–target interaction data
2026-04-01T15:37:00+01:00By Drug Target Review
Most drug–target data were never designed to be compared at scale. Pharmome mapping takes a different approach, building a shared dataset intended to support more predictable discovery.
Interview
Computational design drives new generation of synthetic promoters
2026-03-26T14:21:00+00:00By Drug Target Review
Designing gene control from scratch is becoming possible. SynGenSys is using computational design to create synthetic promoters for advanced therapies.
Interview
Physics-based modelling offers a new way to study drug targets
2026-03-26T14:15:00+00:00By Drug Target Review
Australian start-up OmnigeniQ has demonstrated what it describes as the first deterministic, physics-based computation of a human protein in its native state.

Opinion and interviews

Computational design drives new generation of synthetic promoters

2026-03-26T14:21:00+00:00By Drug Target Review

Designing gene control from scratch is becoming possible. SynGenSys is using computational design to create synthetic promoters for advanced therapies.

Opinion and interviews

Previous
Next

Webinars

Previous
Next

Whitepapers

Previous
Next